Clinical trial
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine…
NCT00309634 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00309634 |
|---|---|
| Title | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years |
| Official title | Observer-blind Monocentric Study in Adults Aged Between 18-60 Years to Evaluate Reactogenicity and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen Doses and Adjuvanted or Not |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines |
| Enrollment | 400 |
| Start date | Mar 27, 2006 |
| Primary completion | Oct 28, 2006 |
| Completion | Oct 28, 2006 |
| First posted | Apr 3, 2006 |
| Last update posted | May 10, 2017 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: